My lab has been involved in the synthesis and characterization of novel compounds (usually dual ligands) based on lipid derivatives for the treatment of metabolic disorders and feeding disorders such as obesity. Our research activity is focused on the in vivo screening of these compounds using animal models (i.e., wild-type and knockout rodents) to identify relevant chemical entities after analyzing behavioral and metabolic effects.

In the present COST Action, my scientific experience is related to the WG: Selection of biological targets and assessment of biological data. I consider that in vivo studies of multitarget drugs during the first stages of evaluation in preclinical models have the potential to offer conclusive insights about the nature of drugs and diseases. Certain side effects derived from central activity (e.g., drugs crossing BBB form systemic administration) and/or additional activity on different targets could be observed using preclinical models and tests. Appropriate approaches should be identified according to the multitarget drug activity and disease of interest.